Publications

Q & A with Principal Investigator

Novartis invites scrutiny of effort to improve access to medicine


Health Affairs

Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence 

We reviewed the initiatives of twenty-one research-based global biopharmaceutical companies to assess their strategies for improving access and the quality of evidence on the impact of their initiatives.


Protocol

BMJ Open: Study protocol for a cluster-randomised controlled trial of an NCD access to medicines initiative: evaluation of Novartis Access in Kenya (Full Protocol)

ClinicalTrials.gov: Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative (Protocol Summary)


Presentations

Dr. Richard Laing’s presentation on the Evaluation of Novartis Access at the World Health Assembly in Geneva, Switzerland, on May 25th, 2016 (Full)

Dr. Richard Laing’s presentation on the Evaluation of Novartis Access at the Ecumenical Pharmaceutical Network forum in Tübingen, Germany, on May 19th, 2016 (Abbreviated)


All Topics (January 21 through March 31)

There are no events in All Topics during the specified time period.